Overview Non-Nucleoside Reverse Transcriptase Inhibitors Perinatal

What's New in the Guidelines
Guidelines Panel Members
Financial Disclosure
Introduction
Maternal HIV Testing and Identification of Perinatal HIV Exposure
Preconception Counseling and Care for Women of Childbearing Age Living with HIV
- Overview
- Reproductive Options for Couples When One or Both Partners are Living with HIV
Antepartum Care
- General Principles Regarding Use of Antiretroviral Drugs during Pregnancy
- Recommendations for Use of Antiretroviral Drugs During Pregnancy
- Monitoring of the Woman and Fetus During Pregnancy
- Antiretroviral Drug Resistance and Resistance Testing in Pregnancy
- Lack of Viral Suppression
- Stopping Antiretroviral Drugs During Pregnancy
- Special Populations
Intrapartum Care
Postpartum Follow-Up of Women Living with HIV Infection
Counseling and Management of Women Living with HIV Who Breastfeed
Management of Infants Born to Women with HIV Infection
Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission
Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
- Table 8. ARV Drug Use in Pregnant Women with HIV
- Overview
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Entry and Attachment Inhibitors
  - Ibalizumab-uiyk (Trogarzo, IBA)
  - Maraviroc (Selzentry, MVC)
- Integrase Inhibitors
- Pharmacoenhancers
  - Cobicistat (Tybost, COBI)
  - Ritonavir (Norvir, RTV)
- Archived Drugs
- Antiretroviral Pregnancy Registry
Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis
Appendix D. Dolutegravir Counseling Guide for Health Care Providers
Appendix E: Acronyms

Download Guidelines

Full Guideline PDF (3 MB)
Recommendations Only PDF (211 KB)
Tables Only PDF (388 KB)

Non-Nucleoside Reverse Transcriptase Inhibitors

Overview

Five non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) are currently U.S. Food and Drug Administration (FDA) approved: delavirdine, efavirenz, etravirine, nevirapine, and rilpivirine. Delavirdine is no longer available in the United States.

Doravirine (Pifeltro, DOR)
Efavirenz (Sustiva, EFV)
Etravirine (Intelence, ETR)
Nevirapine (Viramune, NVP)
Rilpivirine (Edurant. RPV)

Glossary of Terms for Supplement
Glossary of Terms for Supplement
Carcinogenic = producing or tending to produce cancer Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic. Genetic mutations and/or chromosomal damage can contribute to cancer formation. Clastogenic = causing disruption of or breakages in chromosomes Genotoxic = damaging to genetic material such as DNA and chromosomes Mutagenic = inducing or capable of inducing genetic mutation Teratogenic = interfering with fetal development and resulting in birth defects

Download Guidelines

Full Guideline PDF (3 MB)
Recommendations Only PDF (211 KB)
Tables Only PDF (388 KB)

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

Download Guidelines

Related Content

Non-Nucleoside Reverse Transcriptase Inhibitors

Overview

Download Guidelines

Related Content

QUICK LINKS